RESULTS FROM THE ELUCIDATE TRIAL Sudeep Tanwar 1 Walter Gregory 2 The ELUCIDATE Investigators 3 Peter Selby 4 William Rosenberg 5 , 1 Institute for Liver & Digestive Health, 2 Clinical Trials Research Unit (CTRU), Leeds Institute of Clinical Trials Research, 3 UK Secondary Care Gastroenterologists and Hepatologists, 4 Leeds Institute of Molecular Medicine, University of Leeds, UK, 5 University College London Medical School Background: Biomarkers have been validated for the prediction of adverse events in chronic liver disease (CLD) patients with a diagnosis of cirrhosis
N.MinW.et al (2017)
Plasma Metabolite Signature Classifies Male LRRK2 Parkinsons Disease Patients
Choose 5-Amino-1MQ if: You want to boost your overall metabolic rate Energy and endurance improvements appeal to you Youre willing to work with a newer compound Preserving muscle during weight loss is a priority Choose AOD-9604 if: Youre targeting stubborn belly fat specifically You prefer a peptide with extensive safety data You want something you can use for longer periods Youre looking for joint health benefits too Consider both if: You want the most comprehensive fat loss approach You can commit to proper medical supervision Your goal is aggressive body recomposition The Bottom Line Both peptides offer real benefits for weight management, but they work through different mechanisms
Tandem-cleavage linkers improve the in vivo stability and tolerability of antibodydrug conjugates
Thymoquinone (TQ), a bioactive compound of Nigella sativa seeds, has emerged as a therapeutic candidate for various diseases due to its diverse pharmacological properties (11), including antioxidant, anti-inflammatory, antiviral, anticancer (12, 13), antibacterial (14, 15), immunomodulatory (16), anticoagulant (17), antipsychotic, anxiolytic, antidepressant (18), and anticonvulsant activities (19, 20)
